July 25th 2022
The chief medical officer of Triumvira Immunologics discussed promising early results from the company’s phase 1/2 clinical trial.
July 24th 2022
The chief of the oncology branch of the Center for Biologics Evaluation and Research at the FDA discussed how academia and industry can work best with regulatory agencies.
July 23rd 2022
The chief medical officer of Triumvira Immunologics discussed the company’s TAC platform and its versatile target-recognizing domain.
July 19th 2022
Raphaël G. Ognar, chief executive officer and co-founder of NKILT Therapeutics, discussed approaches to help increase patient access to cell therapies.
July 16th 2022
Geoffrey Hodge, chief executive officer of SOTIO Biotech US, discussed the company's development of the BOXR cell therapy platform.
July 12th 2022
The associate director of Research at Senti Biosciences discussed the company's research on using logic-gated CAR-NK cells for the treatment of AML and solid tumors.
July 10th 2022
The chief scientific officer at TScan Therapeutics discussed the company’s SafetyScan technology.
July 8th 2022
The co-founder and executive chairman of TC BioPharm discussed his thoughts on the regulatory, logistical, and quality hurdles of manufacturing cell therapies.
July 8th 2022
The senior director and clinical program leader, Translational Clinical Oncology at Novartis Institutes for BioMedical Research, discussed new data from the phase 1 study.